1,25-dihydroxyvitamin D3 induces LL-37 and HBD-2 production in keratinocytes from diabetic foot ulcers promoting wound healing: an in vitro model.
Gonzalez-Curiel. Irma I; Trujillo. Valentin V; Montoya-Rosales. Alejandra A; Rincon. Kublai K; Rivas-Calderon. Bruno B; deHaro-Acosta. Jeny J; Marin-Luevano. Paulina P; Lozano-Lopez. Daniel D; Enciso-Moreno. Jose A JA; Rivas-Santiago. Bruno B
Key Findings
- Treating keratinocytes from diabetic foot ulcers with 1,25‑(OH)2D3 boosted the genes and protein levels of the antimicrobial peptides LL‑37 and HBD‑2.
- The conditioned media from these treated cells showed real‑world antimicrobial activity against E. coli.
- In vitro wound‑healing assays demonstrated that the same media significantly enhanced keratinocyte migration, a key step in wound closure.
Practical Outcomes
- For biohackers, the takeaway is that boosting active vitamin D levels might help the body produce more LL‑37, potentially improving infection control and wound healing. While the work is still at the cell‑culture stage, it suggests exploring safe, regulated doses of calcitriol (or high‑dose vitamin D3 under medical supervision) as a complementary strategy for chronic skin wounds, especially in diabetic contexts.
Summary
The study found that the active form of vitamin D (1,25‑dihydroxyvitamin D3) can make skin cells from diabetic foot ulcers produce more natural antibiotics called LL‑37 and HBD‑2, which then helped kill bacteria and speed up cell movement in a lab wound‑healing test.
Abstract
Diabetic foot ulcers (DFU) are one of the most common diabetes-related cause of hospitalization and often lead to severe infections and poor healing. It has been recently reported that patients with DFU have lower levels of antimicrobial peptides (AMPs) at the lesion area, which contributes with the impairment of wound healing. The aim of this study was to determine whether 1,25-dihydroxyvitamin D3 (1,25 (OH)2 D3) and L-isoleucine induced HBD-2 and LL-37 in primary cultures from DFU. We developed primary cell cultures from skin biopsies from 15 patients with DFU and 15 from healthy donors. Cultures were treated with 1,25 (OH)2D3 or L-isoleucine for 18 h. Keratinocytes phenotype was identified by western blot and flow cytometry. Real time qPCR for DEFB4, CAMP and VDR gene expression was performed as well as an ELISA to measure HBD-2 and LL-37 in supernatant. Antimicrobial activity, in vitro, wound healing and proliferation assays were performed with conditioned supernatant. The results show that primary culture from DFU treated with 1,25(OH)2D3, increased DEFB4 and CAMP gene expression and increased the production of HBD-2 and LL-37 in the culture supernatant. These supernatants had antimicrobial activity over E. coli and induced remarkable keratinocyte migration. In conclusion the 1,25(OH)2D3 restored the production of AMPs in primary cell from DFU which were capable to improve the in vitro wound healing assays, suggesting their potential therapeutic use on the treatment of DFU.
Study Information
pubmed
2014
2014-10-22T00:00:00.000Z
10.1371/journal.pone.0111355
87
43